Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TELA Bio, Inc.TELA · Entity 7381 | Director | June 04, 2020 | June 08, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TELA Bio, Inc.
Report date June 04, 2020 · Filed June 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2030-06-04 | Direct | 8,806 |
Reported balance
After 2020-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-04 · Grant · Acquired 8,806 · Balance 8,806 F1: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2020 Filed Jun 8, 2020 16:38 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 8,806 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000450 · edgar.xml · derivative · entry 1 Oliva Adele C · CIK 0001339379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,806 Underlying: Common Stock · 8,806 shares Expires 2030-06-04 F1 · derivative.exercise_date: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 446,813 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000420 · edgar.xml · derivative · entry 7 Oliva Adele C · CIK 0001339379 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Quaker Bioventures II, L.P. Disclosed balance after: 446,813 Underlying: Common Stock · 18,096 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 446,813 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001192482-19-000420 · edgar.xml · derivative · entry 6 Oliva Adele C · CIK 0001339379 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Quaker Bioventures II, L.P. Disclosed balance after: 0 Underlying: Series B Preferred Stock · 446,813 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 12,763,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000420 · edgar.xml · derivative · entry 5 Oliva Adele C · CIK 0001339379 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Quaker Bioventures II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 516,947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries A Preferred Stock · Derivative | 8,530,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000420 · edgar.xml · derivative · entry 4 Oliva Adele C · CIK 0001339379 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Quaker Bioventures II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 345,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 516,947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000420 · edgar.xml · nonDerivative · entry 3 Oliva Adele C · CIK 0001339379 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Quaker Bioventures II, L.P. Disclosed balance after: 1,751,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 20:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 345,489 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000420 · edgar.xml · nonDerivative · entry 2 Oliva Adele C · CIK 0001339379 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Quaker Bioventures II, L.P. Disclosed balance after: 1,234,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 20:48 UTC | TELA Bio, Inc. TELA · Entity 7381 | PurchaseCommon Stock | 153,846 | $13.00 | $1,999,998.00 |
DisclosureSEC source: 0001192482-19-000420 · edgar.xml · nonDerivative · entry 1 Oliva Adele C · CIK 0001339379 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Quaker Bioventures II, L.P. Disclosed balance after: 888,664 F1 · balance_after: Reflects 705,530 shares of common stock received as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.